Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist
- PMID: 32379277
- PMCID: PMC7206528
- DOI: 10.1001/jamaoncol.2020.0804
Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist
Abstract
This cohort study examines the association between prescription drug monitoring program mandates with and without a cancer exemption and the percent of oncologists’ patients with any opioid prescription covered by Medicare Part D.
Conflict of interest statement
Figures
Comment in
-
Managing Cancer Pain During the Opioid Epidemic-Balancing Caution and Compassion.JAMA Oncol. 2020 Jul 1;6(7):1103-1104. doi: 10.1001/jamaoncol.2020.0779. JAMA Oncol. 2020. PMID: 32379274 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
